Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Moleculin hits key inflection point as pivotal MIRACLE Phase 3 AML trial completes treatment for first 45 patients
Find out how Moleculin Biotech’s pivotal MIRACLE Phase 3 milestone for Annamycin could reshape treatment for relapsed AML as Q1 2026 data approaches.
FDA grants RMAT designation to Senti Biosciences’ SENTI-202 after strong early AML trial results
Discover how Senti Biosciences’ SENTI-202 earned FDA RMAT designation after strong AML trial data and what it means for patients and investors.
Can Novo Nordisk catch up—or will Lilly run away with the metabolic crown?
Explore how Eli Lilly and Company and Novo Nordisk are battling for dominance in the metabolic health market, and what could decide the next phase of the obesity drug race.
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
Vyome clears final Phase 2 hurdle for VT-1953, sets stage for pivotal FDA trial in high-need cancer care
Vyome advances VT-1953 toward pivotal FDA trials after strong Phase 2 results in malignant fungating wounds. Discover the regulatory and market impact.
Cullinan Therapeutics showcases early AML response with CLN-049 T-cell engager at ASH 2025
Discover how Cullinan Therapeutics’ CLN-049 showed early AML responses at ASH 2025 and what it could mean for future leukemia treatment and investors.
Fate Therapeutics reports encouraging Phase 1 progress for FT819 as off-the-shelf CAR T therapy targets durable lupus remission
Find out how Fate Therapeutics is advancing FT819 as an off-the-shelf CAR T therapy for lupus and why its Phase 1 data could reshape autoimmune treatment.
Roche’s Columvi shows durable three-year overall survival edge over Rituxan in phase III STARGLO trial
Find out how Roche’s Columvi delivered a durable three-year survival advantage in the phase III STARGLO lymphoma trial and what it means for patients and investors.
Oral GLP-1 race heats up as Structure Therapeutics posts strong ACCESS data for aleniglipron
Find out how Structure Therapeutics’ oral GLP-1 drug aleniglipron delivered double-digit weight loss in the ACCESS trial and what it means for the obesity market.